Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0T6QX
|
|||
Former ID |
DNC004118
|
|||
Drug Name |
ZOTEPINE
|
|||
Synonyms |
zotepine; 26615-21-4; Nipolept; Lodopin; Zoleptil; Zotepina; Zotepinum; Compound-4; Zotepina [Spanish]; Zotepinum [INN-Latin]; Zotepina [INN-Spanish]; UNII-U29O83JAZW; 2-Chloro-11-(2-(dimethylamino)ethoxy)dibenzo(b,f)thiepin; 2-Chlor-11-(2-dimethylaminoaethoxy)-dibenzo(b,f)-thiepin; C18H18ClNOS; BRN 1435710; U29O83JAZW; CHEMBL285802; CHEBI:32316; HDOZVRUNCMBHFH-UHFFFAOYSA-N; 2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethylethanamine; 2-Chloro-11-(2-dimethylaminoethoxy)-dibenzo(b,f)thiepine; NCGC00182081-02
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Anxiety disorder [ICD-11: 6B00-6B0Z; ICD-10: R45.0] | Approved | [1], [2] | |
Structure |
![]() |
Download2D MOL |
||
Formula |
C18H18ClNOS
|
|||
Canonical SMILES |
CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl
|
|||
InChI |
1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3
|
|||
InChIKey |
HDOZVRUNCMBHFH-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 26615-21-4
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
5375173, 7848384, 7980920, 8153517, 12013422, 14899864, 29224773, 48416715, 49658668, 49832081, 49962436, 57322922, 74607145, 85174240, 85209606, 85753334, 91749410, 92729688, 103195284, 103993496, 104310109, 109613401, 114919769, 118313787, 124893805, 124893806, 125346524, 128045577, 131308055, 134341323, 134996843, 135651367, 137001502, 142405042, 144206686, 162175576, 162248926, 164829244, 170465934, 175611849, 179150247, 198951716, 224543978, 226486877, 250133641, 252157701, 252418861, 252450828
|
|||
ChEBI ID |
CHEBI:32316
|
|||
SuperDrug ATC ID |
N05AX11
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides uniformis was decreased by Zotepine (adjusted p-values: 9.84E-05). | |||
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides vulgatus was decreased by Zotepine (adjusted p-values: 2.34E-06). | |||
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Parabacteroides distasonis was decreased by Zotepine (adjusted p-values: 3.26E-03). | |||
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Prevotella copri was decreased by Zotepine (adjusted p-values: 4.27E-03). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eubacterium eligens was decreased by Zotepine (adjusted p-values: 1.71E-03). | |||
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eubacterium rectale was decreased by Zotepine (adjusted p-values: 1.84E-03). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
Studied Microbe: Akkermansia muciniphila
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Akkermansia muciniphila was decreased by Zotepine (adjusted p-values: 5.66E-03). |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | 5-HT 2A receptor (HTR2A) | Target Info | Inhibitor | [4] |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Gap junction | ||||
Serotonergic synapse | ||||
Inflammatory mediator regulation of TRP channels | ||||
Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
Reactome | Serotonin receptors | |||
G alpha (q) signalling events | ||||
WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | |||
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
SIDS Susceptibility Pathways | ||||
Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 103). | |||
REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
REF 4 | Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.